63619-83-0

Upstream product

• 63619-82-9 3-(4-methoxyphenyl)-4-(4-methoxybenzoyl)-1,2-dihydronaphthalene 

Downstream Products

• 170847-35-5 3-(4-Methoxyphenyl)-4-(4-diethylaminoethoxybenzoyl)-1,2-dihydronaphthalene, Mesylate Salt 
• 170847-26-4 3-(4-methoxyphenyl)-4-[4-[2-(piperidin-1-yl)ethoxy]benzoyl]-1,2-dihydronaphthalene, citrate salt 
• 145410-83-9 11-(4-hydroxyphenyl)-9-methoxy-11H-benzo[a]fluorene 
• 170847-37-7 3-(4-Methoxyphenyl)-4-(4-diisopropylaminoethoxybenzoyl)-1,2-dihydronaphthalene, Mesylate Salt 
• 170847-28-6 3-(4-Methoxyphenyl)-4-[4-(2-dimethylaminoethoxy)benzoyl]-1,2-dihydronaphthalene, Citrate Salt 

Relevant academic research and scientific papers

Synthesis and antiestrogenic activity of [3,4-dihydro-2-(4-methoxyphenyl)-1-naphthalenyl][4-[2-(1-pyrrolidinyl) ethoxy]-phenyl]methanone, methanesulfonic acid salt

Acylation of the sodio anion of β-tetralone with phenyl anisoate, followed by a Grignard reaction of the resultant 4 with 4-methoxyphenylmagnesium bromide, gave rise to two novel dihydronaphthalene isomers 5 and 6. Regioselective demethylation of either 5 or 6 by NaSEt produced [3,4-dihydro-2-(4-methoxyphenyl)-1-naphthalenyl](4-hydroxyphenyl)methanone (7). Etherification of the phenolic group of 6duced [3,4-dihydro-2-(4-methoxyphenyl)-1-naphthalenyl](4-hydroxyphenyl)methanone (7). Etherification of the phenolic group of 7 by N-(2-chloroethyl)pyrrolidine and subsequent methanesulfonate salt formation provided [3,4-dihydro-2-(4-methoxyphenyl)-1-naphthalenyl][4-2-(1-pyrrolidinyl)ethoxy]phenyl]methanone, methane sulfonic acid salt. Potent antiestrogenic activity of 3 was demonstrated by both oral and subcutaneous administration to rats and mice. In vitro binding studies with rat uterine cystosol estrogen receptors indicate compound 3 has a very high binding affinity which exceeds that of estradiol.